Skip to content

Clinical Research Project on the Reduction of In - stent Restenosis in Coronary Heart Disease by Remote Ischemic Preconditioning Combined with Danshen Decoction

Clinical Research on the Reduction of In - stent Restenosis in Coronary Heart Disease by Remote Ischemic Preconditioning Combined with Danshen Decoction

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002387
Enrollment
Unknown
Registered
2025-12-06
Start date
2022-02-09
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary in - stent restenosis

Interventions

Treatment group:On the basis of conventional treatment ischemic preconditioning therapy combined with the traditional Chinese medicine Danshen Drink was administered for 7 days after admission.
Control group:Given conventional drug therapy including.

Sponsors

Guangdong Provincial Hospital of Chinese Medicine Dade Road General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: (1) The condition meets the diagnostic criteria of both traditional Chinese medicine and Western medicine. (2) Meets the indications for PCI and consents to coronary stent implantation and is accompanied by mild angina pectoris (fewer than one attack per week). (3) Can cooperate to complete treatment and observation indicators. (4) Aged 18-85 years old with normal expressive and communicative abilities. (5) The patient is informed and voluntarily signs the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with chronic kidney disease and severe dysfunction of important organs such as the heart lungs and liver; those with severe primary diseases of the hematopoietic system and endocrine system malignant tumors etc. who are expected to be unable to complete the trial. (2) Patients with uncontrollable systemic infections. (3) Individuals who cannot cooperate with the study due to mental or psychological disorders. (4) Those who have participated in other clinical trials within the past 1 month. (5) Pregnant or planning to become pregnant and lactating women.

Design outcomes

Secondary

MeasureTime frame
The incidence of major adverse cardiac events (MACE);Electrocardiogram (ECG) echocardiography;Creatine phosphokinase isoenzyme (CK-MB) troponin myoglobin high-sensitivity C-reactive protein (hs-CRP) erythrocyte sedimentation rate (ESR);Cardiovascular clinical composite endpoints;

Primary

MeasureTime frame
The incidence and degree of in - stent restenosis in coronary arteries;

Countries

China

Contacts

Public ContactLiuQing

Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital

851757626@qq.com136 3122 3512

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026